U.S., Oct. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07215949) titled 'Zilucoplan for Severe gMG Exacerbations' on Oct. 06.
Brief Summary: This is an open-label, multicenter, interventional phase 3b study in participants with AChR+ gMG and severe exacerbation that require hospitalization. Patients will receive subcutaneous zilucoplan injections daily for 12 weeks. Participation in the study will last for approximately 18 weeks.
Study Start Date: Dec. 01
Study Type: INTERVENTIONAL
Condition:
Generalized Myasthenia Gravis (gMG)
Intervention:
DRUG: Zilucoplan(R)
Subcutaneous injections of zilucoplan will be administered daily. The dose is dependent on the body weight of the patient. Each patient wi...